An Open-Label, Long Term, Safety, and Tolerability Study of VEGF Trap [aflibercept] in Patients With Incurable, Relapsed or Refractory Solid Tumors or Lymphoma.
Phase of Trial: Phase I
Latest Information Update: 14 Jun 2016
At a glance
- Drugs Aflibercept (Primary)
- Indications Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 16 Apr 2013 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 22 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.